IMNM · NASDAQ
Immunome (IMNM) Stock Price & Fundamentals
Immunome (IMNM) closed at $415.21 on Oct 9, 2026, up 1.03% from the previous close of $410.96.
Share price, past year
1Y +50.09%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $415.21 |
| Sep 30, 2026 | $402.93 |
| Aug 31, 2026 | $375.10 |
| Jul 31, 2026 | $386.17 |
| Jun 30, 2026 | $382.80 |
| May 29, 2026 | $363.88 |
| Apr 30, 2026 | $331.13 |
| Mar 31, 2026 | $326.48 |
| Feb 27, 2026 | $300.39 |
| Jan 30, 2026 | $314.01 |
| Dec 31, 2025 | $302.00 |
| Nov 28, 2025 | $280.13 |
| Oct 31, 2025 | $281.44 |
Key statistics
- Market cap
- $47.08B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.54
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$254.32M
- Shares outstanding
- 113.4M
- Dividend yield
- —
- 52-week range
- $271.81 – $415.21
Immunome's market cap is $47.08B, based on a share price of $415.21 and 113.4M shares outstanding as of Jun 30, 2026.
Financials
Immunome reported revenue of $6.94M for fiscal 2025, down 23.23% from fiscal 2024.
Immunome reported a net loss of $212.39M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $6.94M | −23.2% | −$212.39M | −3,060.0% | −$2.43 | −$200.60M |
| FY2024ended Dec 31, 2024 | $9.04M | −35.5% | −$292.96M | −3,240.4% | −$5.00 | −$117.97M |
| FY2023ended Dec 31, 2023 | $14.02M | — | −$106.81M | −761.9% | −$5.38 | −$8.40M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$73.13M | −$0.65 |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$53.84M | −$0.48 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$69.90M | −$0.76 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$57.46M | −$0.65 |
| Q2 FY2025ended Jun 30, 2025 | $4.02M | −$43.40M | −$0.50 |
| Q1 FY2025ended Mar 31, 2025 | $2.93M | −$41.64M | −$0.52 |
| Q4 FY2024ended Dec 31, 2024 | $2.74M | −$80.25M | −$1.11 |
| Q3 FY2024ended Sep 30, 2024 | $2.91M | −$47.10M | −$0.78 |
Company profile
- Name
- Immunome Inc.
- Ticker
- IMNM
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001472012
Recent SEC filings
- Oct 5, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jun 12, 2026
- May 12, 2026
- May 12, 2026
- Mar 3, 2026
- Mar 3, 2026
Frequently asked questions
What is Immunome's stock price?
Immunome (IMNM) closed at $415.21 on Oct 9, 2026, up 1.03% from the previous close of $410.96.
What is Immunome's market cap?
Immunome's market cap is $47.08B, based on a share price of $415.21 and 113.4M shares outstanding as of Jun 30, 2026.
How much revenue does Immunome make?
Immunome reported revenue of $6.94M for fiscal 2025, down 23.23% from fiscal 2024.
Does Immunome pay a dividend?
Immunome's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Immunome Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures